Free Trial

Biomerica (BMRA) Competitors

Biomerica logo
$0.28 +0.01 (+4.85%)
(As of 12/20/2024 05:31 PM ET)

BMRA vs. NNVC, IBIO, MTEX, BFRG, COCP, TENX, CGTX, FNCH, CTXR, and CVKD

Should you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include NanoViricides (NNVC), iBio (IBIO), Mannatech (MTEX), Bullfrog AI (BFRG), Cocrystal Pharma (COCP), Tenax Therapeutics (TENX), Cognition Therapeutics (CGTX), Finch Therapeutics Group (FNCH), Citius Pharmaceuticals (CTXR), and Cadrenal Therapeutics (CVKD). These companies are all part of the "pharmaceutical products" industry.

Biomerica vs.

NanoViricides (NYSE:NNVC) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.

NanoViricides has a net margin of 0.00% compared to Biomerica's net margin of -111.89%. Biomerica's return on equity of -84.62% beat NanoViricides' return on equity.

Company Net Margins Return on Equity Return on Assets
NanoViricidesN/A -84.63% -76.49%
Biomerica -111.89%-84.62%-62.72%

In the previous week, NanoViricides' average media sentiment score of 0.00 equaled Biomerica'saverage media sentiment score.

Company Overall Sentiment
NanoViricides Neutral
Biomerica Neutral

Biomerica has higher revenue and earnings than NanoViricides. NanoViricides is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NanoViricidesN/AN/A-$8.29M-$0.76-1.96
Biomerica$5.51M0.85-$5.98M-$0.37-0.75

10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 4.6% of NanoViricides shares are owned by insiders. Comparatively, 15.0% of Biomerica shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

NanoViricides has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Biomerica has a beta of -1.1, suggesting that its stock price is 210% less volatile than the S&P 500.

Biomerica received 137 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 67.82% of users gave Biomerica an outperform vote while only 0.00% of users gave NanoViricides an outperform vote.

CompanyUnderperformOutperform
NanoViricidesOutperform Votes
No Votes
Underperform Votes
57
100.00%
BiomericaOutperform Votes
137
67.82%
Underperform Votes
65
32.18%

Summary

Biomerica beats NanoViricides on 10 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMRA vs. The Competition

MetricBiomericaDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$4.69M$2.51B$5.14B$9.08B
Dividend YieldN/A0.73%5.09%4.23%
P/E Ratio-0.756.0789.9717.18
Price / Sales0.8575.121,116.21116.99
Price / CashN/A15.0542.8937.86
Price / Book0.723.284.784.78
Net Income-$5.98M$29.98M$120.23M$225.60M
7 Day Performance-11.12%-1.55%-1.92%-1.23%
1 Month Performance-17.26%8.21%11.49%3.36%
1 Year Performance-76.76%-21.46%30.57%16.60%

Biomerica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMRA
Biomerica
0.1425 of 5 stars
$0.28
+4.8%
N/A-80.1%$4.69M$5.51M-0.7560Gap Down
NNVC
NanoViricides
N/A$1.50
+1.4%
N/A+36.7%$20.92MN/A-1.9520
IBIO
iBio
0.988 of 5 stars
$2.28
-1.3%
$4.30
+88.6%
N/A$20.86M$175,000.000.00100
MTEX
Mannatech
0.2128 of 5 stars
$11.06
+6.0%
N/A+43.0%$20.79M$131.96M-13.90250Analyst Forecast
Gap Up
BFRG
Bullfrog AI
0.7327 of 5 stars
$2.36
+6.3%
N/A-27.6%$20.56M$60,000.00-2.864News Coverage
COCP
Cocrystal Pharma
2.6621 of 5 stars
$2.02
+5.9%
$7.00
+246.5%
+21.6%$20.55MN/A-1.1210Positive News
TENX
Tenax Therapeutics
1.4636 of 5 stars
$5.76
-2.0%
$16.00
+177.8%
-76.7%$19.64MN/A0.009News Coverage
CGTX
Cognition Therapeutics
2.9027 of 5 stars
$0.46
-3.7%
$8.00
+1,638.0%
-62.3%$19.13MN/A-0.4920Analyst Forecast
News Coverage
FNCH
Finch Therapeutics Group
N/A$11.75
-2.1%
N/A+264.2%$18.87M$110,000.00-1.36190News Coverage
CTXR
Citius Pharmaceuticals
1.6657 of 5 stars
$2.61
-6.5%
$100.00
+3,731.4%
-86.8%$18.87MN/A-0.4720Gap Down
CVKD
Cadrenal Therapeutics
1.7098 of 5 stars
$11.16
-0.4%
$18.00
+61.3%
N/A$18.51MN/A-1.684News Coverage
Gap Up

Related Companies and Tools


This page (NASDAQ:BMRA) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners